Several of the highly effective treatment options for CRC patients are designed for patients with specific mutations (i.e. KRAS, EGFR, VEGF) or specifically target the immune system, however these approaches are not effective in the majority of CRC patients15. Here, VEGFA is linked to colorectal carcinoma.